A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.

Leijuan GanMengran LangXindi TianShao-Hua RenGuangtao LiYayue LiuRuyu HanKangwei ZhuHuikai LiQiang WuYunlong CuiWei ZhangFeng FangQiang LiTianqiang Song

Published in: Journal of hepatocellular carcinoma (2023)

The triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy can convert potentially unresectable HCC into resectable disease and improve long-term survival.

Keyphrases

combination therapy
locally advanced
liver metastases
stem cells
mesenchymal stem cells